OncoMatch/Clinical Trials/NCT06608732
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Is NCT06608732 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Inaticabtagene autoleucel for b-cell acute lymphoblastic leukemia.
Treatment: Inaticabtagene autoleucel — Evaluate the safety and efficacy of Inaticabtagene autoleucel combined with autologous hematopoietic stem cell transplantation in adolescents or adults with MRD-positive initial complete remission in B-cell acute lymphoblastic leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR BCR-ABL1 > 0% detected by routine q-PCR technology (BCR-ABL1 > 0%)
patients with BCR-ABL1 > 0% detected by routine q-PCR technology
Disease stage
Required: Stage CR1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: induction chemotherapy — standard (Ph-negative) or guideline-recommended (Ph-positive); TKI allowed for Ph-positive
achieving CR1 after standard induction chemotherapy (Ph-negative) or guideline-recommended induction chemotherapy (or use of TKI) (Ph-positive)
Must have received: consolidation therapy — at least one
undergoing at least one consolidation therapy
Cannot have received: CAR-T cell therapy
Individuals who have received CAR-T cell therapy before screening or pre-treatment
Cannot have received: hematopoietic stem cell transplantation
patients who have undergone hematopoietic stem cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify